Advanced searches left 3/3

Dolutegravir - Springer Nature

Summarized by Plex Scholar
Last Updated: 22 June 2022

* If you want to update the article please login/register

Transformation of dolutegravir into an ultra-long-acting parenteral prodrug formulation

Without injection site reactions or systemic toxicities, a single parenteral dose of dolutegravir prodrug nanocrystals maintains a 90 percent inhibitory concentration for up to a year. Following single parenteral injection, we show that the physiochemical and pharmacokinetic formulation characteristics help with drug release from tissue macrophage depot stores at the muscle injection site and adjacent lymphoid tissues. Both resource poor and wealthy settings can be used to reduce HIV-1 transmission and achieve optimal treatment results by using a NM2DTG drug to reduce HIV-1 transmission and optimal treatment results.

Source link: https://doi.org/10.1038/s41467-022-30902-7


A randomized comparison of health-related quality of life outcomes of dolutegravir versus efavirenz-based antiretroviral treatment initiated in the third trimester of pregnancy

In a clinical trial in Uganda and South Africa, we compared HRQoL among treatment-nau00efve pregnant women randomly assigned to dolutegravir- or efavirenz-based ART. The primary study findings were physical health summary and mental health summary ratings, while the 11 MOS-HIV subscales were secondary findings. HRQoL scores increased from baseline in both treatment arms: PHS and MHS for dolutegravir-based ART; PHS and MHS for efavirenz-based ART. PHS results in the dolutegravir-based arm were higher, as the dolutegravir-based arm's differences were higher, though MHS were not as high for women in the efavirenz-based armat 24 and 48 weeks. An increase in MHS scores was found with higher PHS scores after owning a bank account, using the internet, and longer treatment duration were all factors that contributed to an increase in MHS scores in the multivariate analysis. Conclusion In late pregnancy, there were no significant differences in HRQoL outcomes among HIV-positive women who started on dolutegravir relative to efavirenz.

Source link: https://doi.org/10.1186/s12981-022-00446-3


Shorter Time to Discontinuation Due to Treatment Failure in People Living with HIV Switched to Dolutegravir Plus Either Rilpivirine or Lamivudine Compared with Integrase Inhibitor-Based Triple Therapy in a Large Spanish Cohort

Introduction Two nucleoside analogue reverse transcriptase inhibitors mixed with a third agent was used to develop a standard HIV treatment regimen. Methods All patients in the Spanish VACH cohort were randomized to INSTI-based 3DR or a 2DR composed of DTG + RPV or DTG + 3TC between May 2, 2016, 2016 and May 15, 2019. There was a 2. 33 percent hazard ratio for discontinuation due to TF on 2DR vs. 3DR. Conclusion In the real world, the dangers of discontinuation due to TF and VF were more than two times higher in patients switching to DTG-based 2DR than INSTI-based 3DR, with no difference in discontinuation due to AEs. To prevent HIV infection from spreading, people living with HIV need lifelong care. Standard HIV drugs use three different drugs in combination, but they can also cause unwanted side effects. 616 participants were divided into two groups in Spain, with 564 participants switching from their old treatment to a three-drug regimen, and 617 participants moved to a two-drug regimen, while 617 were converted to a two-drug regimen. The researchers figured out how long it took for the participants to stop taking their medications because it wasn't effective or it caused too many side effects. Those taking a 2DR stopped sooner than those taking a 3DR. Of the 30% of participants who stopped treatment because it stopped working. Participants in a 2DR were twice as likely to stop therapy because it was not effective than those receiving a 3DR.

Source link: https://doi.org/10.1007/s40121-022-00630-y

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions